<DOC>
	<DOC>NCT02389790</DOC>
	<brief_summary>The primary objectives of the study are: -To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）</brief_summary>
	<brief_title>Extension Study of MT-1303 in Subjects With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>The subject completed 14 week Treatment Period in the double blind MT1303E13 study as per Protocol. Permanent discontinuation of study medication prior to the end of treatment Visit in MT1303E13</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>